Cancer and Blood Services

Our Cancer and Blood Services team leads the way in commissioning specialised and innovative healthcare services to meet the diverse needs of our community.

Within our portfolio, we prioritise the provision of Advanced Therapeutic Medicinal Products (ATMPs), ensuring patients have access to cutting-edge treatments tailored to their unique conditions. Our focus on Lymphoma services involves commissioning comprehensive diagnostic and therapeutic interventions, including genetic testing and specific treatments such as BMT and CAR-T therapies.

We strategically commission Genomic services to utilise genetic insights for personalized treatment approaches, optimizing patient outcomes. Collaborating with leading providers, we commission specific aspects of liver cancer surgery (limited to South Wales), the Hepatocellular Carcinoma MDT, liver ablation, selective internal radiation therapy (SIRT), and stereotactic ablative body radiotherapy (SABR).

Our role in immunology centers specifically on primary immunodeficiency management, promoting access to specialised care and therapies.

We ensure the availability of state-of-the-art PET and PBT services separately, facilitating precise imaging and radiation therapies for cancer patients.

Our commissioning efforts extend to the treatment of Sarcoma and Thoracic Surgery, providing multidisciplinary care for complex malignancies and thoracic conditions.

As stewards of healthcare commissioning, we are guided by a commitment to excellence, equity, and innovation. We strive to optimise healthcare delivery and outcomes through strategic partnerships, evidence-based practices, and continuous quality improvement initiatives.